Associate Director/Director, New Oncology Product Innovation

San Carlos, California, United States

Apply with AI Apply

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

Candidates must possess a Bachelor's degree in life sciences, biomedical engineering, or a related field, with an advanced degree (PhD, MD, MBA) preferred. A minimum of 7 years of experience in product management, strategy, or innovation within oncology, diagnostics, pharma, or academic research settings is required. Demonstrated experience working with biopharma clients and/or academic collaborators in oncology or precision medicine is essential, along with a proven ability to lead early-stage product innovation. Strong understanding of clinical trial processes, biomarker development, and the research pipeline dynamics relevant to oncology is necessary. Expertise in financial modeling, market analysis, and business case development tailored to biopharma and academic customer needs, as well as excellent communication and leadership skills, are crucial.

Responsibilities

The Associate Director/Director will lead the discovery, evaluation, and early development of novel oncology products for biopharma and academic customers. Responsibilities include engaging with biopharma partners for companion diagnostics and biomarker-driven product development, collaborating with academic researchers for co-development, and conducting Voice of Customer interviews to define unmet needs. The role involves developing and prioritizing product concepts, guiding the evaluation of emerging technologies, and leading cross-functional teams in proof-of-concept studies. Additionally, the position requires driving strategic pipeline prioritization, supporting due diligence for external innovation, and acting as a cross-functional champion for customer-centric innovation.

Skills

Oncology

Product Innovation

Biopharma

Academic Research

Genomics

AI/ML

Companion Diagnostics

Clinical Trials

Biomarker Development

Market Research

Product Strategy

Proof-of-Concept

Feasibility Assessment

Pipeline Prioritization

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Austin, TexasHeadquarters

2004Year Founded

$149.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

1,001-5,000Employees

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.

New Prospera Heart features may face slow adoption by healthcare providers.

Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.

Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.

Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.

AI integration enhances accuracy and speed of Natera's cfDNA analysis.

Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI

Try Jobo Free